Expert Opin Drug Saf. 2020;19(10):1349-1356.
The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
제1저자 박혜정 · 교신저자 강혜련, 이용원
소속 (11)
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine , Seoul, Republic of Korea.
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital , Seongnam, Republic of Korea.
- Department of Pediatrics, Inje University Haeundae Paik Hospital , Busan, Republic of Korea.
- Department of Internal Medicine, Kosin University College of Medicine , Busan, Republic of Korea.
- Department of Internal Medicine, Keimyung University Dongsan Medical Center , Daegu, Republic of Korea.
- Department of Internal Medicine, SMG-SNU Boramae Medical Center , Seoul, Republic of Korea.
- Drug Safety Monitoring Center, Seoul National University Hospital , Seoul, Republic of Korea.
- Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital , Seoul, Republic of Korea.
- Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine , Incheon, Republic of Korea.
Abstract
BACKGROUND The human leukocyte antigen (HLA)-B*13:01 was reported as an important risk factor for dapsone hypersensitivity syndrome (DHS) in Chinese and Thai populations.
RESEARCH DESIGN AND METHODS From the Korean nationwide registry, seven subjects with previous DHS were included. Their HLA allele/phenotype frequencies were compared with 8 dapsone-tolerant subjects recruited from a single institution, and general population (n = 485) in Korea. The authors also performed a meta-analysis with these data using previous Chinese and Thai studies.
RESULTS Among the seven DHS subjects, 85.7% presented with the HLA-B*13:01 allele. The HLA-C*03:04, HLA-DRB1*12:02 (both in linkage disequilibrium with HLA-B*13:01), and HLA-A*02:01 alleles were also presented in 85.7%, 71.4%, and 71.4%, respectively. Subjects with HLA-B*13:01 were susceptible to developing DHS compared to dapsone-tolerant controls (odds ratio [OR]: 73.667) and the Korean general population (OR: 139.500). HLA-C*03:04 (OR: 40.935), HLA-DRB*12:02 (OR: 36.613), and HLA-A*02:01 (OR: 5.862) showed similar results. In meta-analysis, HLA-B*13:01 was associated with dapsone-induced hypersensitivity (overall OR: 42.692), and subgroup analyses according to the control types demonstrated similar results (OR:43.694 and 41.866, respectively).
CONCLUSIONS Similar to previous Asian population studies, HLA-B*13:01 is significantly associated with the risk of DHS in Korea. These associations may be useful for preventing DHS and improving drug safety.
Keywords
DapsoneHLA-B*13:01human leukocyte antigenhypersensitivity syndrome
그 밖의 정보
- 출판 형태
- Journal Article, Meta-Analysis
- 저널
- Expert opinion on drug safety · eISSN 1744-764X
- 전자 출판
- 2020-08-18
- MeSH
- Adult · Aged · Asian People / genetics · Child · Dapsone / administration & dosage / adverse effects · Drug Hypersensitivity Syndrome / etiology / genetics · Female · Genotype · HLA-B13 Antigen / genetics · Humans · Leprostatic Agents / administration & dosage / adverse effects · Male · Middle Aged · Registries · Republic of Korea · Risk Factors
- Substances
- HLA-B13 Antigen · Leprostatic Agents · Dapsone